AbbVie's Stock Performance and Recent Acquisition

AbbVie's stock has outperformed the S&P 500, rising 16% since November 2023. The company's acquisition of ImmunoGen for $10 billion and its flagship drug Elahere, a first-in-class antibody-drug conjugate, have contributed to its success. Despite the impending patent cliff for its top-selling drug Humira, AbbVie's diversified portfolio and innovative pipeline suggest a promising future.